Last updated: February 15, 2026
Overview
NDC 00310-7560 corresponds to the drug omalizumab, marketed as Xolair. Approved for indications such as moderate to severe allergic asthma, chronic idiopathic urticaria, and nasal polyps, omalizumab is administered via subcutaneous injection. The drug's market has experienced steady growth, driven by expanding indications and increasing adoption in clinical settings.
Market Size and Growth Trends
The global omalizumab market was valued at approximately USD 3.2 billion in 2022 and is projected to reach USD 5.5 billion by 2027, exhibiting a compound annual growth rate (CAGR) of 11.7% (source: IQVIA, 2022). Key factors include:
- Rising prevalence of allergies and asthma.
- Expanded approval for nasal polyps (FDA, 2020).
- Increasing adoption in developed markets and emerging economies.
Key Market Drivers
- Expanded Approved Indications: The approval of omalizumab for nasal polyps in 2020 broadened the market scope.
- Low Penetration in Some Markets: Growing awareness and insurance reimbursement in the U.S. and Europe.
- Patient Pool Growth: Rising allergic disease prevalence correlates with increased therapy demand.
Competitive Landscape
| Company |
Market Share |
Notable Products |
Key Insights |
| Novartis (Xolair) |
Leading (~95%) |
Xolair |
Dominates global sales; patent protected in key markets |
| Other Players |
Minor |
Igeva, Ligelizumab (in trials) |
Emerging competitors; still in clinical phases |
Pricing Analysis
- Current Selling Price: The average wholesale price (AWP) for a single 150 mg dose in the U.S. ranges from USD 840 to USD 950.
- Annual Treatment Cost: For asthma, typical dosing is 300 mg every four weeks, translating to approximately USD 10,200 annually.
- Reimbursement Trends: Insurance coverage varies, with reimbursement rates impacting net prices.
Price Projections (Next 5 Years)
| Year |
Estimated Average Wholesale Price per Dose |
Notes |
| 2023 |
USD 900 |
Stable; market competition remains limited |
| 2024 |
USD 930 |
Slight increase due to inflation and production costs |
| 2025 |
USD 950 |
Potential price stabilization; biosimilar entry in select markets anticipated |
| 2026 |
USD 930 |
Biosimilar competition may push prices downward |
| 2027 |
USD 900 |
Expected to stabilize amid continued biosimilar development |
Biosimilar Impact: Biosimilars for omalizumab are under development and expected to enter markets in Europe and possibly the U.S. by 2025-2026. They could reduce prices by 20-40%, influencing market share and pricing strategies.
Regulatory and Policy Influences
- Prices are sensitive to regulatory decisions, patent protections, and biosimilar approvals.
- The expiration of key patents in the U.S. and Europe is expected starting around 2024-2025.
- Potential policy shifts favoring biosimilar adoption could accelerate price erosion.
Summary
Omalizumab maintains a robust market with growth prospects fueled by expanding indications and unmet needs. Nonetheless, biosimilar entries and patent expirations are likely to exert downward pressure on prices over the next 3–4 years. Market growth is steady, supported by increasing disease prevalence and ongoing clinical research.
Key Takeaways
- The global omalizumab market is expected to grow at around 11.7% annually until 2027.
- Current U.S. wholesale prices hover around USD 900 per dose, translating to annual costs exceeding USD 10,000 per patient.
- Biosimilar competition could reduce net prices by up to 40% starting in 2025.
- Patent expirations starting in 2024 will influence pricing and market dynamics.
- The expanding scope of indications offers market growth opportunities while increasing competitive pressure.
FAQs
1. When will biosimilars for omalizumab likely hit the market?
Biosimilars are projected to be approved in Europe as early as 2024 and possibly in the U.S. by 2025-2026, contingent on regulatory processes.
2. How will patent expirations affect the market?
Patent expirations beginning in 2024 will enable biosimilar entry, increasing competition, and likely reducing prices by 20–40%.
3. Are there alternative therapies affecting market growth?
New biologics targeting allergic and respiratory conditions are in development, but none currently match omalizumab’s market dominance.
4. What is the cost outlook for patients?
Average annual treatment costs are stable but may decrease with biosimilar adoption, especially in markets with aggressive price competition.
5. What regulatory trends could impact pricing?
Policies promoting biosimilar use and international trade agreements can influence drug pricing and market access globally.
Citations
[1] IQVIA, 2022. Global Market Report on Omalizumab.
[2] U.S. FDA, 2020. Approval of Xolair for Nasal Polyps.
[3] Novartis Annual Reports, 2022.
[4] European Medicines Agency, 2021. Biosimilar Development.
[5] MarketWatch, 2023. Omalizumab Price Trends.
